Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer

Key facts

Sponsor

Mayo Clinic

Principal Investigator

Joel G. Fletcher, MD

Mayo Clinic in Rochester

Intervention

PCD-CT(procedure)

Enrollment

200 enrolled

Eligibility

18-99 years · All sexes

Timeline

2024 – 2026

Study locations (1)

• Mayo Clinic in Rochester, Rochester, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Paraneoplastic cerebellar degeneration

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07144280
  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
  Pfizer
• ACTIVE NOT RECRUITINGPHASE2NCT05557591
  A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
  Regeneron Pharmaceuticals
• RECRUITINGNANCT06080841
  Curcumin Supplementation in Cervical Cancer
  National Institute of Cancerología
• ACTIVE NOT RECRUITINGPHASE1NCT05338775
  A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
  Janssen Research & Development, LLC

See all trials for Paraneoplastic cerebellar degeneration →